Fornasiero A, Daniele O, Fosser V P, Paccagnella A, Salvagno L, Sileni V C, Morandi P, Fiorentino M V
Cancer Treat Rep. 1986 May;70(5):647-9.
A clinical evaluation of peptichemio (40-45 mg/m2/day for 3 days every 3-4 weeks) was conducted in 32 patients with advanced breast cancer, 28 of whom were evaluable for both toxicity and response. The overall response rate was 18% (one complete remission and four partial remissions), with a median duration of 4 months (range, 2-6). The major side effects were cumulative myelotoxicity, phlebitis, mild nausea, and vomiting. A posttreatment heparin infusion was used to prevent phlebitis.
对32例晚期乳腺癌患者进行了培西化疗（每3 - 4周一次，40 - 45毫克/平方米/天，共3天）的临床评估，其中28例患者可评估毒性和反应。总缓解率为18%（1例完全缓解，4例部分缓解），中位缓解持续时间为4个月（范围2 - 6个月）。主要副作用为累积性骨髓毒性、静脉炎、轻度恶心和呕吐。采用治疗后肝素输注预防静脉炎。
